Bristol Myers wins US FDA approval for new type of schizophrenia drug
WEB22 hours ago · Sept 26 (Reuters) - The U.S. Food and Drug Administration approved Bristol Myers Squibb's (BMY.N) schizophrenia drug late on Thursday, making it the first new type of antipsychotic medicine in ...
U.S. Food and Drug Administration Approves Bristol Myers Squibb…
WEB20 hours ago · PRINCETON, N.J., September 27, 2024--U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
U.S. Food and Drug Administration Approves Bristol Myers Squibb…
WEB20 hours ago · PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY™ (xanomeline and trospium chloride), an ...
FDA approves Bristol Myers Squibb's schizophrenia drug
WEB22 hours ago · The Food and Drug Administration approved Bristol Myers Squibb’s highly anticipated schizophrenia drug, the first novel type of treatment for the debilitating, chronic mental disorder in more ...
Bristol Myers Squibb Receives U.S. Food and Drug Administration …
WEBAug 21, 2024 · PRINCETON, N.J.-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for Opdivo ® (nivolumab) plus Yervoy ® (ipilimumab) as potential first-line treatment for adult patients with unresectable hepatocellular carcinom...
Bristol Myers Squibb - U.S. Food and Drug Administration …
WEBMay 30, 2024 · PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted approval for Breyanzi ® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or …
Bristol Myers (BMY) Gets US Nod for First New Schizophrenia Drug …
WEB22 hours ago · September 27, 2024 at 4:21 AM EDT. Save. Bristol Myers Squibb Co.gained US approval for the first new type of schizophrenia drug in seven decades, opening a fresh avenue of treatment for millions ...
Bristol-Myers Squibb stock jumps on schizophrenia drug approval
WEB12 hours ago · Bristol-Myers Squibb shares rose in premarket trade on Friday after the U.S. Food and Drug Administration approved a schizophrenia drug. Bristol-Myers shares BMY jumped 6% to a five-month high in ...
Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets …
WEB7 hours ago · Bristol Myers Squibb's drug to treat schizophrenia was approved for use by the Food and Drug Administration. The pharmaceutical firm called Cobenfy the first new treatment for the illness in decades.
Bristol Myers Squibb - U.S. Food and Drug Administration …
WEB10 hours ago · PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY™ (xanomeline and trospium chloride), an oral medication for the treatment of schizophrenia in adults. 1 COBENFY represents the first new class of medicine in several decades and introduces a fundamentally new approach to treating ...
- Some results have been removed